Showing results (121-130 of 188) with videos related to

Sort By:
Pageof 19
Archives of Neurology|December 17, 2003
Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosisMartin Hardmeier, Stefan Wagenpfeil, Peter Freitag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 17, 2005
Longitudinal single-cell cytokine responses reveal recurrent autoimmune myelin reactivity in relapsing--remitting multiple sclerosis patientsI R Moldovan, R A Rudick, A C Cotleur, et al.
Neurology|May 29, 2001
Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MSR A Rudick, G Cutter, M Baier, et al.
Neurology|October 10, 2001
Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MSR Zivadinov, R A Rudick, R De Masi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 6, 2005
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patientsR A Rudick, G R Cutter, M Baier, et al.
Neurology|March 23, 2005
Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosisM L Baier, G R Cutter, R A Rudick, et al.
Neurology|June 6, 2014
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS StudyPaul O'Connor, Andrew Goodman, Ludwig Kappos, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 13, 2014
Factors associated with clinically significant increased walking time in multiple sclerosis: results of a survival analysis of short-term follow-up data from a clinical databaseDeborah M Miller, Nicolas R Thompson, Jeffrey A Cohen, et al.
Neurology|May 6, 2011
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosisP W O'Connor, A Goodman, L Kappos, et al.
Methods (San Diego, Calif.)|May 3, 2003
Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytesPia Kivisäkk, Zhugong Liu, Corinna Trebst, et al.
Pageof 19